Cipla Share Price in Focus as USFDA Classifies Goa Facility Inspection as Voluntary Action Indicated

Cipla Limited has announced that the United States Food and Drug Administration (USFDA) has classified its recent inspection at the company's manufacturing facility in Verna, Goa, as Voluntary Action Indicated (VAI).  

This inspection took place between April 6 and April 17, 2026, and was part of routine current Good Manufacturing Practices (cGMP) and Pre-Approval Inspection (PAI) processes. 

Details of the USFDA Inspection 

The inspection at Cipla's Goa facility was conducted by the USFDA to ensure compliance with cGMP standards and to carry out a Pre-Approval Inspection.  

The inspection occurred over a period of 12 days, from April 6 to April 17, 2026. The classification of Voluntary Action Indicated. 

Communication from USFDA 

On June 10, 2026, at 22:17 hours IST, Cipla received official communication from the USFDA regarding the inspection outcome.  

The VAI classification indicates that the company is expected to address the identified issues voluntarily without the need for formal corrective action. 

Read More: Alembic Pharma Share Price in Focus After Getting Tentative Approval From USFDA for Cancer Drug Larotrectinib! 

Cipla Share Price Performance 

As of June 11, 2026, at 2:04 PM, Cipla share price on NSE was trading at ₹1,385.70 up by 0.63% from the previous closing price. 

Conclusion 

Cipla's Goa facility underwent a USFDA inspection from April 6 to April 17, 2026, resulting in a Voluntary Action Indicated classification. The USFDA communicated this outcome on June 10, 2026, allowing Cipla to address the observations voluntarily. 

Track the stock market in Hindi. Visit Angel One News for the latest market trends, insights, and share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.